secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001193125-24-139364
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero Therapeutics Q1 net loss $12.7M; SPR720 Phase 2a data expected 2H 2024
----------------------------------------------------------------------------

- Net loss $12.7M ($0.24/share) vs $13.3M ($0.25/share) in Q1 2023; revenue $9.3M up from $2.1M.
- Cash $82.3M at March 31, 2024, increased from $76.3M after receiving $23.8M milestone from GSK for tebipenem HBr.
- SPR720 Phase 2a top-line data for NTM-PD expected 2H 2024; tebipenem HBr Phase 3 PIVOT-PO enrollment ongoing, completion 2H 2025.
- SPR206 received FDA Fast Track designation for HABP/VABP due to CRABc and CRPA; Phase 2 contingent on non-dilutive funding.
- Reaffirmed cash runway into late 2025 based on current operating plans.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312524139364/0001193125-24-139364-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312524139364/d756109d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-139364

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer